Daniela Mercatelli

Enhancement of D1 dopaminergic responses in aged LRRK2 G2019S knock-in mice

Viral mediated α-synuclein overexpression results in greater transgene levels and α-synuclein overload in mice bearing kinase dead mutation of LRRK2

Development of a new toolbox for mouse PET–CT brain image analysis fully based on CT images and validation in a PD mouse model

Dopamine Transporter, PhosphoSerine129 α-Synuclein and α-Synuclein Levels in Aged LRRK2 G2019S Knock-In and Knock-Out Mice

Constitutive silencing of LRRK2 kinase activity leads to early glucocerebrosidase deregulation and late impairment of autophagy in vivo

In vivo susceptibility to energy failure parkinsonism and LRRK2 kinase activity

Early Dysfunction of Substantia Nigra Dopamine Neurons in the ParkinQ311X Mouse

Regulator of G‐Protein Signalling 4 (RGS4) negatively modulates nociceptin/orphanin FQ opioid receptor signalling: Implication for <scp>l</scp>‐Dopa‐induced dyskinesia

RGS4 negatively modulates Nociceptin/Orphanin FQ opioid receptor signaling: implication for L-Dopa induced dyskinesia

Constitutive Silencing of LRRK2 Kinase Activity Leads to Early Glucocerebrosidase Deregulation and Late Impairment of Autophagy in vivo

Pharmacological antagonism of kainate receptor rescues dysfunction and loss of dopamine neurons in a mouse model of human parkin-induced toxicity

Discovery and Structure–Activity Relationships of Nociceptin Receptor Partial Agonists That Afford Symptom Ablation in Parkinson’s Disease Models

Pharmacological Antagonism of Kainate Receptor Rescues Dysfunction and Loss of Dopamine Neurons in a Mouse Model of Human Parkin-induced Toxicity

Gene Co-expression Analysis Identifies Histone Deacetylase 5 and 9 Expression in Midbrain Dopamine Neurons and as Regulators of Neurite Growth via Bone Morphogenetic Protein Signaling

Leucine‐rich repeat kinase 2 (<scp>LRRK</scp>2) inhibitors differentially modulate glutamate release and Serine935 <scp>LRRK</scp>2 phosphorylation in striatal and cerebrocortical synaptosomes

Managing Parkinson's disease: moving ON with NOP

Leucine-rich repeat kinase 2 controls protein kinase A activation state through phosphodiesterase 4

Influence of neuropathic pain on nicotinic acetylcholine receptor plasticity and behavioral responses to nicotine in rats

NOP Receptor Ligands and Parkinson’s Disease

Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice

Anti‐Parkinsonian and anti‐dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists

Parkinson’s disease: no NOP, new hope

Eltoprazine prevents levodopa‐induced dyskinesias by reducing striatal glutamate and direct pathway activity